Sign in to view content

ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su, MD

Video
Published 2023

Related

Phase 3 GUARD Trial of ADX-2191 (Methotrexate for Intravitreal Administration) to Prevent Proliferative Vitreoretinopathy and Other Postoperative Complications
Christina Joy Flaxel, MD
Annual Meeting Talks
2023
Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Toxicity: RELIEF Trial Results
Karen M Wai, MD
STEPHEN J SMITH, MD
Updates from the Field
2025
Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization
Glenn C. Yiu, MD, PhD
Updates from the Field
2019

Category: Diabetic Retinopathy

See more